- Home
- SKIL vs VIGL Comparison
SKIL vs VIGL Comparison
Compare SKIL & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIL
- VIGL
- Stock Information
- Founded
- SKIL 1998
- VIGL 2020
- Country
- SKIL United States
- VIGL United States
- Employees
- SKIL N/A
- VIGL N/A
- Industry
- SKIL Computer Software: Prepackaged Software
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SKIL Technology
- VIGL Health Care
- Exchange
- SKIL Nasdaq
- VIGL Nasdaq
- Market Cap
- SKIL 128.9M
- VIGL 141.5M
- IPO Year
- SKIL N/A
- VIGL 2022
- Fundamental
- Price
- SKIL $14.48
- VIGL $3.00
- Analyst Decision
- SKIL Strong Buy
- VIGL Buy
- Analyst Count
- SKIL 4
- VIGL 5
- Target Price
- SKIL $36.67
- VIGL $16.80
- AVG Volume (30 Days)
- SKIL 30.3K
- VIGL 51.3K
- Earning Date
- SKIL 12-03-2024
- VIGL 11-07-2024
- Dividend Yield
- SKIL N/A
- VIGL N/A
- EPS Growth
- SKIL N/A
- VIGL N/A
- EPS
- SKIL N/A
- VIGL N/A
- Revenue
- SKIL $536,511,999.00
- VIGL N/A
- Revenue This Year
- SKIL N/A
- VIGL N/A
- Revenue Next Year
- SKIL $3.46
- VIGL N/A
- P/E Ratio
- SKIL N/A
- VIGL N/A
- Revenue Growth
- SKIL N/A
- VIGL N/A
- 52 Week Low
- SKIL $5.09
- VIGL $2.47
- 52 Week High
- SKIL $20.20
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- SKIL 36.72
- VIGL 32.87
- Support Level
- SKIL $13.91
- VIGL $2.89
- Resistance Level
- SKIL $15.02
- VIGL $3.26
- Average True Range (ATR)
- SKIL 0.73
- VIGL 0.22
- MACD
- SKIL -0.15
- VIGL -0.08
- Stochastic Oscillator
- SKIL 22.89
- VIGL 9.40
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Content & Platform and Instructor-Led Training. The Content & Platform business engages in the sale, marketing and delivery of its content learning solutions, in areas such as Leadership and Business, Technology and Developer and Compliance. The Instructor-Led Training business offers training solutions covering information technology and business skills for corporations and their employees. The majority of revenue is from the Content & Platform segment.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.